Regulatory Status of Acne Actives: US FDA OTC Drug Monograph & EU Cosmetic Limits

Overview #

The regulatory gap between the US and EU on acne actives is wider than most brand owners realize — and it shapes every formulation decision we make before a single gram hits the mixer. In the US, benzoyl peroxide, salicylic acid, and a handful of others sit inside the FDA OTC Drug Monograph system, which means concentration limits, labeling requirements, and drug-fact panels are non-negotiable. In the EU, the same ingredients are regulated under the EU Cosmetics Regulation 1223/2009 as cosmetic actives — different ceiling concentrations, different claims language, different everything. When brand partners come to us wanting a single global SKU for acne, the first thing we tell them is: that’s probably not possible. Not without compromise.

The Established Actives: What the Monograph Actually Allows #

Salicylic acid is the workhorse. Under the FDA OTC monograph for acne, it’s permitted at 0.5–2.0% in leave-on formats. Under EU cosmetics regulation, it’s restricted to 2.0% in face products with a mandatory “not for use on children under 3 years” warning. So the ceiling is the same — but the regulatory pathway to get there is completely different. In the US, you’re filing as an OTC drug. In the EU, you’re formulating a cosmetic with a restricted ingredient declaration.

Benzoyl peroxide is where things get complicated fast. The FDA monograph permits 2.5–10% for OTC acne treatment. The EU, as of the SCCS Scientific Opinion updates, has been progressively tightening its position — BPO is not freely permitted as a cosmetic ingredient in the EU, and most brands selling into Europe either reformulate or accept that their BPO product simply won’t be marketed there. We’ve had clients come to us with a 5% BPO brief for a “global launch.” That conversation usually ends with two separate formulas.

Adapalene and tretinoin are prescription-only in most markets. We don’t formulate those for OTC. Full stop.

Sulfur is underused. Honestly, most brands overlook it because it smells and the aesthetics are harder to work with. But at 3–5%, it’s genuinely effective for inflammatory acne, it’s monograph-compliant in the US, and it doesn’t carry the EU regulatory headache that BPO does. We’ve formulated sulfur-based spot treatments that perform well in stability — the challenge is masking the odor without pushing fragrance load so high it creates its own irritation problem.

Next-Generation and Alternative Actives: Where the Market Is Actually Moving #

This is where the brief conversations get more interesting. Brands are coming to us with ingredients like azelaic acid, zinc PCA, bakuchiol, and various peptide-adjacent actives, asking whether they can make acne claims. Short answer: it depends entirely on which market and what claim you want to make.

Azelaic acid sits in a regulatory grey zone that we navigate carefully. In the EU, it’s used as a cosmetic active — no specific restriction in Annex III or IV, so it’s permissible under general safety assessment. In the US, it’s not in the OTC monograph, which means you cannot make a drug claim (“treats acne”) on a product containing only azelaic acid without going through NDA or 505(b)(2). What you can do is make cosmetic-adjacent claims around “blemish-prone skin” or “uneven texture.” Most of our clients targeting the US market with azelaic acid are using 5–10% and staying firmly in cosmetic claim territory. We’ve seen this work commercially. Whether the clinical evidence fully supports the claims being made — we’re still not entirely convinced across the board.

Niacinamide at 4–5% is probably the most commercially successful “acne-adjacent” cosmetic active right now, and it’s not in any monograph. It works through sebum regulation and anti-inflammatory pathways rather than direct antimicrobial action, which is why it stays on the cosmetic side of the line. One double-blind RCT (n=76, 8 weeks) comparing 4% niacinamide gel to 1% clindamycin gel showed comparable reduction in inflammatory lesion count — roughly 60% reduction in both arms. What that study doesn’t tell you is the stability story at scale, which is where we’ve had to do our own work. Niacinamide hydrolyzes to nicotinic acid above pH 7.0 and at elevated temperatures, causing flushing complaints. We formulate it at pH 5.5–6.5 and run 40°C/75% RH stability for a minimum of 12 weeks before we sign off on any formula.

Zinc PCA is interesting for sebum control. We use it at 0.5–1.0% in combination formulas. It’s not a standalone acne active — no one should be claiming that — but as part of a multi-active system targeting oily, blemish-prone skin, it contributes meaningfully. Cost is low. Stability is good. It’s one of those ingredients that earns its place quietly.

Bakuchiol is a different story. The retinol-alternative positioning has been heavily marketed, and some of that marketing has bled into acne territory. We’ve formulated bakuchiol at 0.5–1.0% for clients wanting a “clean” alternative to retinoids for acne-prone skin. The clinical evidence for acne specifically is thin. For anti-aging, there’s more data. We’re honest with clients about this distinction.

For brands interested in how these actives interact with broader skin barrier considerations, our acne & blemish control formulation resources cover the full active selection framework we use internally.

Where Most Brands Get This Wrong #

The single most common mistake we see: brands brief us on a 2% salicylic acid serum for the US market, we formulate it, it passes stability, and then six months later they want to launch the same SKU in the EU with the same label. The formula might be fine. The label is not. The US version has a Drug Facts panel. The EU version needs a standard INCI list and a cosmetic product safety report (CPSR) under EU regulation. These are not interchangeable documents.

The second mistake is pH. Salicylic acid is only meaningfully active in its free acid form, which requires pH below 4.0 for significant free acid fraction. Drop below pH 3.5 and you’re in regulatory grey territory in the EU for leave-on products — the SCCS has flagged low-pH leave-on products as a dermal penetration concern. Most brands don’t realize this until we tell them. We formulate SA leave-ons at pH 3.5–4.0 and we don’t go lower, even when clients push for “stronger” performance.

The third mistake is packaging. We had a client insist on a jar format for a 2% SA treatment. Worked fine at 500g lab scale. At 150kg production, we saw pH drift of 0.3 units over 8 weeks at 40°C — not catastrophic, but enough to push us outside our validated range. The issue was headspace oxidation interacting with the preservative system. We switched to an airless pump. The client pushed back on cost — airless adds roughly $0.50–$0.90 per unit at MOQ 3,000 — but the stability data made the argument for us. It’s not a perfect solution for every price point, but for actives-heavy formulas, it’s usually the right call.

This is usually where projects go sideways: the packaging decision gets made before the formulation is validated, and then we’re retrofitting stability data to a container that wasn’t designed for the formula.

Stability Profiles and Cost Considerations #

Stability is not uniform across this category. Benzoyl peroxide is the most demanding — it’s an oxidizing agent, it degrades packaging, it bleaches fabric, and it requires specific container materials (typically HDPE or specific grades of PP). We run BPO formulas at 25°C/60% RH and 40°C/75% RH per ICH Stability Guidelines adapted for OTC drug products, and we require a minimum 18-month projected shelf life before we release a formula for commercial production.

Salicylic acid is more forgiving but still pH-sensitive. Niacinamide is stable in the right pH window. Azelaic acid is actually quite stable — one of the easier actives to work with from a formulation standpoint.

Cost-effectiveness varies significantly. Salicylic acid is cheap — we’re talking cents per kilogram at the concentrations used. BPO is more expensive and the handling requirements add manufacturing cost. Azelaic acid at 10% adds meaningful COGS. Encapsulated actives — and some brands are now requesting encapsulated SA or encapsulated BPO for reduced irritation — roughly triple the raw material cost. We’ve stopped quoting encapsulated BPO to clients who haven’t already accepted that cost reality upfront. Most haven’t.

For brands exploring how encapsulation technology affects active delivery and cost in this category, our encapsulation technology documentation covers the trade-offs in detail.

The NMPA Cosmetic Regulation adds another layer for brands targeting China. Salicylic acid is permitted in cosmetics at up to 2% for acne-prone skin claims, but the registration pathway for functional cosmetics (特殊化妆品) is lengthy — typically 12–18 months — and BPO is not on the permitted list for cosmetics at all. Brands wanting to sell acne-positioned products in China need to plan their active selection around NMPA’s positive list from day one, not as an afterthought.

Supplier Qualification Checklist #

When we qualify a new active ingredient supplier for this category, these are the non-negotiables we work through before a single gram goes into a development batch:

Documentation requirements:
– Certificate of Analysis (CoA) with batch-specific assay results — not a generic spec sheet
– Heavy metals panel: lead ≤10 ppm, arsenic ≤3 ppm, mercury ≤1 ppm (aligned with EU and NMPA limits)
– Microbial limits: TAMC ≤100 CFU/g for actives going into leave-on formulas
– Residual solvent data for any synthetic actives (ICH Q3C limits)
– Stability data at 25°C/60% RH and 40°C/75% RH — minimum 6 months from supplier, we run our own in parallel

Regulatory documentation:
– REACH compliance letter for EU-destined products
– MSDS/SDS current version
– For BPO specifically: UN transport classification documentation and packaging compliance
– Country-of-origin documentation (this matters for tariff classification and some market registrations)

Manufacturing site:
– GMP certification — ISO 22716 for cosmetic-grade actives, or equivalent pharmaceutical GMP for drug-grade BPO
– Audit report or willingness to accept third-party audit
– Contamination control procedures for oxidizing agents (BPO-specific)

We rejected one BPO supplier two years ago because their GMP documentation was current but their contamination control SOP hadn’t been updated since 2019 and didn’t reflect their facility expansion. The paperwork looked fine. The facility visit told a different story. We now require a facility visit or third-party audit report dated within 24 months for any new active ingredient supplier in this category.

One thing we’ve learned: supplier qualification is not a one-time event. We re-qualify annually for critical actives and require notification of any manufacturing site changes. We’ve had two instances where a supplier changed their synthesis route without proactive notification — both times we caught it in our incoming QC, but it delayed production batches by 3–4 weeks. That’s a lesson we only needed to learn once.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask every brand that comes to us with an acne brief — because the answers determine everything from active selection to label architecture to packaging format.

If you’re targeting the US with drug claims (“treats acne,” “reduces acne blemishes”), you need to be inside the OTC monograph. That means salicylic acid at 0.5–2.0%, BPO at 2.5–10%, or sulfur at 3–10%, with a Drug Facts panel and compliant labeling. We handle the formulation; you need a US regulatory consultant for the labeling sign-off.

If you’re targeting the EU with cosmetic positioning, your active toolkit shifts. BPO is effectively off the table. Salicylic acid at up to 2% with the required warning is your primary option for a recognized acne active. Niacinamide, azelaic acid, zinc PCA, and botanical actives like willow bark extract (which contains salicin, not salicylic acid — a distinction that matters for claims) give you a broader palette for cosmetic-claim products.

If you want a single global formula, we can usually get there with a niacinamide-led system at 4–5%, supported by zinc PCA and a low-level salicylic acid at 0.5–1.0% — a concentration that sits inside both the FDA monograph floor and the EU cosmetic limit. The trade-off is that you’re making cosmetic claims in both markets, not drug claims in the US. Some brands are fine with that. Others aren’t.

Minimum order quantities for actives-heavy formulas in this category typically start at 500kg finished product for BPO-containing formulas due to handling requirements. For SA-based and cosmetic-active formulas, we can work from 200kg.

Frequently Asked Questions #

Q: We want to put “2% salicylic acid” on the front of pack for the US market — is that straightforward?

Yes, but it triggers OTC drug status, which means Drug Facts panel, specific labeling language (“For the treatment of acne”), and your product is regulated as a drug, not a cosmetic. The formulation itself isn’t complicated at 2% SA — we do it regularly. The regulatory paperwork and labeling compliance is where brands underestimate the workload. Budget for a US OTC regulatory consultant alongside the formulation project.

Q: Can we use benzoyl peroxide in our EU launch?

Practically speaking, no. BPO is not listed as a permitted cosmetic ingredient in the EU annexes, and the SCCS has not issued a positive opinion supporting its use in leave-on cosmetics. Some brands have tried to position BPO products as medical devices in the EU — that pathway exists but it’s significantly more complex and expensive than a cosmetic registration. For most indie brands, the answer is to reformulate for EU with SA, niacinamide, or azelaic acid.

Q: What’s the minimum effective concentration for niacinamide in an acne formula?

The clinical data we find most credible points to 4% as the threshold for meaningful sebum regulation and anti-inflammatory effect. We formulate at 4–5% for acne-positioned products. Below 4%, you can still include it for skin barrier support, but we’d be cautious about making acne-specific claims at lower concentrations. At 5%, you’re also getting meaningful brightening effect on post-inflammatory hyperpigmentation, which is a real consumer benefit in this category.

Q: We’ve seen “willow bark extract” marketed as a natural salicylic acid alternative — does it work the same way?

Not exactly, and this matters for claims. Willow bark contains salicin, which converts to salicylic acid in the body after ingestion — but topical conversion is minimal and inconsistent. It’s not equivalent to formulated salicylic acid for acne treatment purposes, and you cannot make OTC drug claims based on willow bark extract. What it does offer is mild exfoliating and anti-inflammatory activity as a cosmetic active, and it avoids the SA warning label requirements in the EU. We use it at 0.5–2.0% extract (standardized to salicin content) in cosmetic formulas where the brand wants a “clean” or botanical positioning.

Q: How long does stability testing take before we can launch?

For a US OTC drug product, we require a minimum of 18 months projected shelf life supported by real-time and accelerated data — that means at least 6 months of real-time data at 25°C/60% RH plus accelerated data at 40°C/75% RH before we’re comfortable with a 2-year shelf life claim. For EU cosmetic formulas, the CPSR requires stability data but the specific timeline is risk-based — for a straightforward SA or niacinamide formula in validated packaging, we typically have sufficient data at 12 weeks accelerated plus 3 months real-time. Total timeline from brief to launch-ready stability package: plan for 6–9 months minimum.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.